Literature DB >> 22373822

Assessment of the green florescence protein labeling method for tracking implanted mesenchymal stem cells.

Yinghua Guo1, Longxiang Su, Junlou Wu, Dong Zhang, Xiaojun Zhang, Guizhi Zhang, Tianzhi Li, Junfeng Wang, Changting Liu.   

Abstract

Although green fluorescent protein (GFP) labeling is widely accepted as a tracking method, much remains uncertain regarding the retention of injected GFP-labeled cells implanted in ischemic organs. In this study, we evaluate the effectiveness of GFP for identifying and tracking implanted bone marrow- mesenchymal stem cells (BM-MSCs) and the effect of GFP on the paracrine actions of these cells. MSCs isolated from rat femur marrow were transduced with a recombinant adenovirus carrying GFP. After transplantation of the GFP-labeled BM-MSCs into the infarct zone of rat hearts, the survival, distribution, and migration of the labeled cells were analyzed at 3, 7, 14, and 28 days. To evaluate the effect of GFP on the paracrine actions of BM-MSCs, Western blot analysis was performed to detect the expression of vascular endothelial growth factor (VEGF), b fibroblast growth factor (b FGF), tissue inhibitor of metalloproteinase-1 (TIMP-1) and matrix metalloproteinases-2 (MMP-2). GFP was successfully expressed by BM-MSCs in vitro. At 14 days after cell transplantation the GFP-positive cells could not be detected via confocal microscopy. By using a GFP antibody, distinct GFP-positive cells could be seen and quantitative analysis showed that the expression volume of GFP was 6.42 ± 0.92 mm(3) after 3 days, 1.24 ± 0.76 mm(3) after 7 days, 0.33 ± 0.03 mm(3) after 14 days, and 0.09 ± 0.05 mm(3) after 28 days. GFP labeling did not adversely affect the paracrine actions of BM-MSCs. GFP labeling could be used to track MSC distribution and their fate for at least 28 days after delivery to rat hearts with myocardial infarction, and this stem cell tracking strategy did not adversely affect the paracrine actions of BM-MSCs.

Entities:  

Year:  2012        PMID: 22373822      PMCID: PMC3397108          DOI: 10.1007/s10616-011-9417-y

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  30 in total

1.  Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium.

Authors:  Jing Huang; Zhiping Zhang; Jian Guo; Aiguo Ni; Arjun Deb; Lunan Zhang; Maria Mirotsou; Richard E Pratt; Victor J Dzau
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

Review 2.  Cell tracing techniques in stem cell transplantation.

Authors:  Li Yan; Ying Han; Yuanlong He; Huahong Xie; Jingmei Liu; Lina Zhao; Jingbo Wang; Liuchun Gao; Daiming Fan
Journal:  Stem Cell Rev       Date:  2007-12       Impact factor: 5.739

3.  In vitro and in vivo differentiation of mesenchymal stem cells in the cardiomyocyte direction.

Authors:  P V Kruglyakov; I B Sokolova; N N Zin'kova; S K Viide; G V Aleksandrov; N S Petrov; D G Polyntsev
Journal:  Bull Exp Biol Med       Date:  2006-10       Impact factor: 0.804

4.  Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells.

Authors:  Merced Leiker; Gen Suzuki; Vijay S Iyer; John M Canty; Techung Lee
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

5.  Impact of magnetic labeling on human and mouse stem cells and their long-term magnetic resonance tracking in a rat model of Parkinson disease.

Authors:  Albrecht Stroh; Johannes Boltze; Katharina Sieland; Katharina Hild; Cindy Gutzeit; Tobias Jung; Jenny Kressel; Susann Hau; Doreen Reich; Tilman Grune; Claus Zimmer
Journal:  Mol Imaging       Date:  2009 May-Jun       Impact factor: 4.488

6.  Fluorescent protein tracking and detection: fluorescent protein structure and color variants.

Authors:  Mark A Rizzo; Michael W Davidson; David W Piston
Journal:  Cold Spring Harb Protoc       Date:  2009-12

7.  In vivo fluorescence imaging of muscle cell regeneration by transplanted EGFP-labeled myoblasts.

Authors:  Xiaoyin Xu; Zhong Yang; Qiang Liu; Yaming Wang
Journal:  Mol Ther       Date:  2010-02-02       Impact factor: 11.454

8.  Hepatocyte growth factor and granulocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy.

Authors:  Ying-Hua Guo; Jian-Guo He; Jun-Lou Wu; Long Yang; Dong-Sheng Zhang; Xiao-Yan Tan; Rui-Dong Qi
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

9.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Authors:  Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman
Journal:  J Am Coll Cardiol       Date:  2009-12-08       Impact factor: 24.094

10.  Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation.

Authors:  Kirsten A Keyser; Karen E Beagles; Hans-Peter Kiem
Journal:  Cell Transplant       Date:  2007       Impact factor: 4.064

View more
  8 in total

1.  Immunogenicity of allogeneic mesenchymal stem cells transplanted via different routes in diabetic rats.

Authors:  Le-Hui Gu; Tian-Tian Zhang; Yang Li; Hong-Jie Yan; Hui Qi; Fu-Rong Li
Journal:  Cell Mol Immunol       Date:  2014-09-22       Impact factor: 11.530

Review 2.  Bone repair with skeletal stem cells: rationale, progress to date and clinical application.

Authors:  Elena A Jones; Peter V Giannoudis; Dimitrios Kouroupis
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-01       Impact factor: 5.346

3.  Finding and tracing human MSC in 3D microenvironments with the photoconvertible protein Dendra2.

Authors:  Hugo R Caires; Maria Gomez-Lazaro; Carla M Oliveira; David Gomes; Denisa D Mateus; Carla Oliveira; Cristina C Barrias; Mário A Barbosa; Catarina R Almeida
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

Review 4.  Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis.

Authors:  Leah A Marquez-Curtis; Anna Janowska-Wieczorek
Journal:  Biomed Res Int       Date:  2013-12-05       Impact factor: 3.411

5.  Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results.

Authors:  Hongwei Yu; Gregory Fischer; Allison D Ebert; Hsiang-En Wu; Xiaowen Bai; Quinn H Hogan
Journal:  Mol Pain       Date:  2015-02-12       Impact factor: 3.395

6.  Mineralocorticoid receptor deficiency improves the therapeutic effects of mesenchymal stem cells for myocardial infarction via enhanced cell survival.

Authors:  Xinxing Xie; Yunli Shen; Jing Chen; Zheyong Huang; Junbo Ge
Journal:  J Cell Mol Med       Date:  2018-12-13       Impact factor: 5.310

7.  Microglia-derived CCL2 has a prime role in neocortex neuroinflammation.

Authors:  Mariella Errede; Tiziana Annese; Nicole Kerlero de Rosbo; Daniela Virgintino; Valentina Petrosino; Giovanna Longo; Francesco Girolamo; Ignazio de Trizio; Antonio d'Amati; Antonio Uccelli
Journal:  Fluids Barriers CNS       Date:  2022-08-30

Review 8.  Nanoparticles based stem cell tracking in regenerative medicine.

Authors:  Matthew Edmundson; Nguyen Tk Thanh; Bing Song
Journal:  Theranostics       Date:  2013-07-23       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.